• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2021; 45(3) s071-s075

Pubblicato on-line:

Aprile 6, 2021

DOI:

10.19186/BC_2021.013

Scarica in PDF:

Potenziale ruolo dell’Human Epididymis Protein 4 come biomarcatore nella nefropatia mesangiale a depositi di IgA
Potential role of Human Epididymis Protein 4 (HE4) as biomarker for IgA Nephropathy

AUTORI

Annalisa Schirinzi1, Giulia Fontò2, Francesco Pesce2, Angela Calamita1, Renato Contino1, Loreto Gesualdo12,
Francesca Di Serio1
1UOC Patologia Clinica Ospedaliera, Azienda Ospedaliero-Universitaria Policlinico Bari
2UOC Nefrologia, Dialisi e Trapianto, Dipartimento Emergenza e Trapianti di Organi Azienda Ospedaliero-Universitaria Policlinico Bari

ABSTRACT

Potential role of Human Epididymis Protein 4 (HE4) as biomarker for IgA Nephropathy

Introduction: Human Epididymis Secretory Protein 4 (HE4) serum concentrations have been widely investigated in patients with ovarian cancer. However, high levels of HE4 can be also found in other tumors and in renal fibrosis. The aim of this study was to assess serum HE4 levels in a cohort of patients with IgA Nephropathy (IgAN) and the correlation of this potential biomarker with the degree of fibrosis.
Methods: the study included 63 Italian patients with histological diagnosis of IgAN (41 males and 22 females) where HE4 was measured at the time of renal biopsy using a chemiluminescent assay (Abbott Laboratories, Wiesbaden, Germany). The biopsy was scored according to the current Oxford classification using MEST score. The relationship between HE4 and each of the MEST parameters was analyzed by a non-parametric method. A ROC curve analysis was performed to assess the diagnostic accuracy of HE4 in identifying the presence of fibrosis.
Results: serum HE4 concentrations were significantly increased across the progressive degrees of fibrosis related T parameter (p <0.0001) [(median; interquartile range (IQR): T0 = 57.5 pmo/L (43.7-100.7); T1 = 106.0 pmo/L (78.0-149.0); T2 = 210.5 pmo/L (148.2-320.2)]. The ROC curve analysis, after adjusting for age and sex, showed that HE4 is diagnostic for the presence of fibrosis with an Area Under the Curve of 0.79 (95%CI: 0.68-0.91).
Conclusions: the relationship between serum level of HE4 and the degree of interstitial fibrosis suggests the potential role of HE4 as useful biomarker in IgAN.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967